2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Clinical Cancer Drugs
Clinical cancer drugs are the cornerstone of modern oncology, offering hope and progress in the battle against this complex disease. These drugs undergo rigorous testing through clinical trials to evaluate their safety and efficacy in treating various types of cancer. From chemotherapy agents that target rapidly dividing cancer cells to targeted therapies aimed at specific molecular pathways, the arsenal of clinical cancer drugs continues to expand, driven by advancements in research and technology. Immunotherapy, a groundbreaking approach that harnesses the body's immune system to fight cancer, has revolutionized treatment options for many patients. Additionally, the development of precision medicine, which tailors treatment based on the genetic makeup of tumors, holds promise for more personalized and effective therapies. As researchers delve deeper into understanding the molecular mechanisms driving cancer progression, the future of clinical cancer drugs remains bright, offering renewed hope for patients and clinicians alike.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China